60
The aim of the revised EMA system is to reduce costs and generally be more flexible in order to better orientate ourselves to needs. Specifically, the current flat-rate system is intended to become a cost-based system. In addition, only a single legal instrument is planned for all fees in the area of pharmacovigilance and approvals. Many of the changes are also aimed at strengthening the role of the EMA Management Board.